DOI:
10.1055/s-00000094
Zeitschrift für Gastroenterologie
LinksClose Window
References
Indini A, Di Nicola M, Del VecchioM. et al.
Immune suppression and response to ipilimumab: assessing risk-to-benefit ratio.
J Clin Oncol 2016;
34: 1017-1018
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.